Zacks Research Has Optimistic Outlook of BHC Q3 Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Equities research analysts at Zacks Research lifted their Q3 2025 earnings per share estimates for Bausch Health Companies in a research note issued to investors on Tuesday, December 17th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.15 per share for the quarter, up from their previous estimate of $1.12. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.74 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2025 earnings at $1.25 EPS.

Bausch Health Companies (NYSE:BHC) last posted its earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. The firm had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.42 billion. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The business’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.03 EPS.

Other research analysts have also issued research reports about the company. Royal Bank of Canada raised their price objective on Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 1st. Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. Finally, StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $7.75.

Bausch Health Companies Price Performance

Shares of Bausch Health Companies stock opened at $7.39 on Friday. The firm has a market cap of $2.67 billion, a price-to-earnings ratio of -15.40 and a beta of 0.69. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The company has a 50-day moving average of $8.35 and a 200 day moving average of $7.27.

Hedge Funds Weigh In On Bausch Health Companies

Institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC purchased a new stake in Bausch Health Companies in the second quarter worth about $35,000. MQS Management LLC bought a new stake in Bausch Health Companies during the 2nd quarter worth approximately $71,000. Certuity LLC bought a new position in shares of Bausch Health Companies in the second quarter worth approximately $75,000. Bfsg LLC raised its position in shares of Bausch Health Companies by 46.7% during the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after purchasing an additional 3,643 shares during the period. Finally, Kendall Capital Management purchased a new position in shares of Bausch Health Companies during the 2nd quarter valued at $87,000. 78.65% of the stock is owned by institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.